Home
/
BIOMARIN PHARMACEUTICAL INC
/
Financials
/
Quarterly
BIOMARIN PHARMACEUTICAL INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BIOMARIN PHARMACEUTICAL INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$373.45M
Apr 27, 2018
Q3
2017
Sep 30, 2017
$334.15M
Oct 31, 2017
Q2
2017
Jun 30, 2017
$317.45M
Aug 2, 2017
Q1
2018
Mar 31, 2017
$303.75M
Apr 27, 2018
Q3
2017
Sep 30, 2016
$279.90M
Oct 31, 2017
Q2
2017
Jun 30, 2016
$300.13M
Aug 2, 2017
Q1
2017
Mar 31, 2016
$236.74M
May 4, 2017
Q3
2016
Sep 30, 2015
$208.90M
Nov 3, 2016
Q2
2016
Jun 30, 2015
$250.14M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$202.92M
May 2, 2016
Q3
2015
Sep 30, 2014
$176.55M
Nov 2, 2015
Q2
2015
Jun 30, 2014
$191.79M
Aug 5, 2015
Q1
2015
Mar 31, 2014
$151.55M
May 5, 2015
Q3
2014
Sep 30, 2013
$136.87M
Oct 28, 2014
Q2
2014
Jun 30, 2013
$136.81M
Jul 31, 2014
Q1
2014
Mar 31, 2013
$127.93M
May 2, 2014
Q3
2013
Sep 30, 2012
$128.12M
Oct 28, 2013
Q2
2013
Jun 30, 2012
$124.02M
Jul 29, 2013
Q1
2013
Mar 31, 2012
$116.65M
Apr 29, 2013
Q3
2012
Sep 30, 2011
$113.43M
Oct 29, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$776.13M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$825.41M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$745.15M
May 2, 2025
Q3
2025
Sep 30, 2024
$745.74M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$712.03M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$648.83M
May 2, 2025
Q3
2024
Sep 30, 2023
$581.33M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$595.28M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$596.42M
Apr 26, 2024
Q3
2023
Sep 30, 2022
$505.34M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$533.80M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$519.36M
Apr 28, 2023
Q3
2022
Sep 30, 2021
$408.74M
Oct 28, 2022
Q2
2022
Jun 30, 2021
$501.69M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$486.03M
Apr 29, 2022
Q3
2021
Sep 30, 2020
$476.78M
Oct 29, 2021
Q2
2021
Jun 30, 2020
$429.49M
Jul 30, 2021
Q1
2021
Mar 31, 2020
$502.07M
Apr 30, 2021
Q3
2020
Sep 30, 2019
$461.10M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$387.76M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.74M)
Oct 28, 2025
Q2
2025
Jun 30, 2025
$240.53M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$185.69M
May 2, 2025
Q3
2025
Sep 30, 2024
$106.08M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$107.17M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$88.66M
May 2, 2025
Q3
2024
Sep 30, 2023
$40.38M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$56.04M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$50.85M
Apr 26, 2024
Q3
2023
Sep 30, 2022
($6.65M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
$27.66M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$120.80M
Apr 28, 2023
Q3
2022
Sep 30, 2021
($36.49M)
Oct 28, 2022
Q2
2022
Jun 30, 2021
$12.94M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$17.37M
Apr 29, 2022
Q3
2021
Sep 30, 2020
$784.80M
Oct 29, 2021
Q2
2021
Jun 30, 2020
($29.18M)
Jul 30, 2021
Q1
2021
Mar 31, 2020
$81.38M
Apr 30, 2021
Q3
2020
Sep 30, 2019
$55.04M
Nov 6, 2020
Q2
2020
Jun 30, 2019
($37.44M)
Aug 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($46.69M)
Oct 28, 2025
Q2
2025
Jun 30, 2025
$276.89M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$223.89M
May 2, 2025
Q3
2025
Sep 30, 2024
$113.89M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$120.45M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$88.46M
May 2, 2025
Q3
2024
Sep 30, 2023
$30.53M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$65.57M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$62.40M
Apr 26, 2024
Q3
2023
Sep 30, 2022
($2.42M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
$39.15M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$137.33M
Apr 28, 2023
Q3
2022
Sep 30, 2021
($53.22M)
Oct 28, 2022
Q2
2022
Jun 30, 2021
$11.67M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$25.09M
Apr 29, 2022
Q3
2021
Sep 30, 2020
($55.94M)
Oct 29, 2021
Q2
2021
Jun 30, 2020
($40.95M)
Jul 30, 2021
Q1
2021
Mar 31, 2020
$104.96M
Apr 30, 2021
Q3
2020
Sep 30, 2019
$4.01M
Nov 6, 2020
Q2
2020
Jun 30, 2019
($41.35M)
Aug 5, 2020